Summary: Evaluated ivabradine versus placebo in patients with symptomatic systolic heart failure (EF < 35%) in sinus rhythm and heart rate > 70 beats per minute. The primary composite endpoint of cardiovascular death or hospitalization for heart failure was reduced. This was mostly from reduced heart failure admissions.

Original Publication:

N Engl J Med. 2005 Jan 20;352(3):225-37.

Eponym: Systolic Heart Failure Treatment with If Inhibitor Ivabradine Trial